Neumora Therapeutics Stock (NASDAQ:NMRA), Analyst Ratings, Price Targets, Predictions

The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by RBC Capital on March 28, 2024. The analyst firm set a price target for $31.00 expecting NMRA to rise to within 12 months (a possible 220.58% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Neumora Therapeutics (NASDAQ: NMRA) was provided by RBC Capital, and Neumora Therapeutics reiterated their outperform rating.

There is no last upgrade for Neumora Therapeutics.

There is no last downgrade for Neumora Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on March 28, 2024 so you should expect the next rating to be made available sometime around March 28, 2025.

While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a reiterated with a price target of $0.00 to $31.00. The current price Neumora Therapeutics (NMRA) is trading at is $9.67, which is within the analyst’s predicted range.